Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCLA UCSF
Dates
study started
completion around

Description

Summary

The purpose of this clinical trial is to learn about the safety and effects of study medicine (PF-06873600) when taken alone or with hormone therapy by people with cancer.

People may be able to participate in this study if they have the following types of cancer: Hormone Receptor positive (HR+) breast cancer; Human Epidermal Growth Factor Receptor 2 (HER2)-negative breast cancer that is advanced or metastatic (spread to other parts of the body); triple negative breast cancer; epithelial ovarian cancer; fallopian tube cancer; or primary peritoneal cancer.

All participants in this study will receive the study medicine by mouth, 1 to 2 times a day at home. The dose of the study medicine may be changed during the study.

Some participants will also receive hormone therapy. The hormone therapy will be either letrozole by mouth once a day at home, or fulvestrant as a shot into the muscle. Fulvestrant will be given every two weeks at the study clinic for the first month, and then once a month after that.

Participants will take part in this study for at least 7 to 8 months, depending on how they respond to the therapy. During this time participants will visit the study clinic once a week.

Official Title

PHASE 1/2A DOSE ESCALATION AND EXPANSION STUDY EVALUATING SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMICS AND ANTI-TUMOR ACTIVITY OF PF-06873600 AS A SINGLE AGENT AND IN COMBINATION WITH ENDOCRINE THERAPY

Details

This is a Phase 1/2a, open-label, multi-center, non-randomized, multiple dose, safety, tolerability, pharmacokinetic, and pharmacodynamic study of PF-06873600 administered as a single agent in sequential dose levels and then in combination with endocrine therapy. In Part 1A and Part 1C, successive cohorts of patients will receive escalating doses of PF-06873600 and then in dose finding (Part 1B) with PF-06873600 in combination with endocrine therapy (ET). This study contains 2 parts, dose escalation with single agent (Part 1A and 1C) and then dose finding with PF-06873600 in combination with endocrine therapy (Part 1B) followed by dose expansion arms of PF-06873600 in combination with endocrine therapy (Part 2).

Keywords

HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer, Hormone Receptor (HR) Positive Breast Cancer, Estrogen receptor (ER) positive, Progesterone receptor (PR) positive, Cyclin-dependent kinase (CDK), Human epidermal growth factor receptor 2 (HER2) negative, Advanced breast cancer, Metastatic breast cancer (MBC), Triple negative breast cancer (TNBC), Epithelial ovarian cancer (EOC), Fallopian tube cancer, Primary peritoneal cancer (PPC), CDK4/6 inhibitor, Endocrine Therapy (ET), Measurable disease, Luteinizing Hormone Releasing Hormone (LHRH) Agonist, Goserelin, Leuprolide acetate, Breast Neoplasms, Ovarian Neoplasms, Triple Negative Breast Neoplasms, Fallopian Tube Neoplasms, Male Breast Neoplasms, Endocrine Therapy 1, Endocrine Therapy 2

Eligibility

You can join if…

Open to people ages 18 years and up

  • Have a diagnosis of Hormone Receptor Positive (HR+), Human Epidermal Growth Factor Receptor 2 Negative (HER2-) breast cancer

    • Prior combined CDK 4/6 inhibitor and endocrine therapy and 1 or 2 prior lines of chemotherapy

  • Have a diagnosis of metastatic triple negative breast cancer (TNBC)

    • Up to 1-2 prior lines of chemotherapy

  • Have a diagnosis of advanced platinum resistant epithelial ovarian cancer (EOC)/fallopian tube cancer/primary peritoneal cancer (PPC)

    • Up to 2-3 prior lines of therapy

  • Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1
  • Measurable disease or non-measurable disease and refractory to or intolerant of existing therapies (Part 1)
  • Measurable disease as defined by RECIST 1.1 is required (Part 1B and Part 2 only)

You CAN'T join if...

  • Known active uncontrolled or symptomatic Central Nervous System (CNS) metastases
  • Other active malignancy within 3 years prior to randomization, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ
  • Major surgery or radiation within 4 weeks prior to study entry
  • Last anti-cancer treatment within 2 weeks prior to study entry
  • Participation in other studies involving investigational drug(s) within 4 weeks prior to study entry
  • Pregnant or breastfeeding female patients
  • Active inflammatory gastrointestinal (GI) disease, known diverticular disease or previous gastric resection or lap band surgery including impairment of gastro intestinal function or GI disease

Locations

  • UCSF Helen Diller Family Comprehensive Cancer Center
    San Francisco California 94143 United States
  • UCSF Investigational Drugs Pharmacy
    San Francisco California 94158 United States
  • UCLA Hematology/Oncology - Parkside
    Santa Monica California 90404 United States
  • UCLA Hematology/Oncology - Santa Monica
    Santa Monica California 90404 United States
  • The Oncology Institute of Hope and Innovation
    Santa Ana California 92705 United States
  • The Oncology Institute of Hope and Innovation
    Glendale California 91204 United States
  • The Oncology Institute of Hope and Innovation
    Long Beach California 90805 United States
  • The Oncology Institute of Hope and Innovation
    Whittier California 90602 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Pfizer
Links
To obtain contact information for a study center near you, click here.
ID
NCT03519178
Phase
Phase 2 research study
Study Type
Interventional
Participants
About 155 people participating
Last Updated